April 22 was one of those days where you open your feed and three unrelated neuro stories are sitting there, and you realize they actually rhyme.
First one.
LB Pharmaceuticals got its Phase 2 NOVA-1 data on LB-102 published in JAMA Psychiatry.
LB-102 is a once-daily oral benzamide hitting D2, D3, and 5-HT7, pitched as a potential first-in-class benzamide antipsychotic in the U.S.
The readout: statistically significant efficacy in acute schizophrenia, rapid onset, low EPS, minimal sedation. They didn’t put effect sizes in the release, so we’ll see what the paper actually shows.
But a clean tolerability profile on a D2 antagonist, if it holds, is not a small thing. Phase 3 NOVA-2 is queued up, with bipolar depression and MDD studies to follow.
Second one.
Alterity Therapeutics presented new ATH434 Phase 2 data at the AAN late-breaker. Multiple System Atrophy, 52 weeks, reduction in disease progression on the MuSyCA composite across both the functional and neurological components.
No numbers in the release, which is annoying, but AAN late-breakers usually come with the deck.
MSA patients have almost nothing. Any credible disease-modification signal in a synucleinopathy is a story worth paying attention to, and the jump to Phase 3 suggests Alterity thinks the effect is real.
Third one.
AbbVie announced a $1.4B manufacturing campus in Durham, North Carolina. Sterile injectables, 185 acres, 734 permanent jobs, online by 2028.
Not a science story on its face. But the release specifically names neuroscience as one of three portfolios the plant will feed, alongside immunology and oncology.
When a top-five pharma puts its largest-ever single-site capex behind capacity that explicitly includes neuro, that’s a read on where they think their pipeline is going.
Three stories, one day.
A psychiatric small molecule betting on a better D2 antagonist. A rare-disease program chasing disease modification in a synucleinopathy. And a pharma building the physical plant to make the next decade of drugs, with neuro on the list of what gets made there.
If you’d told me a few years ago that all three of those would read as “normal neuro news,” I might not have believed you.